Developing liver-targeted naringenin nanoparticles for breast cancer endocrine therapy by promoting estrogen metabolism

• Published in: Journal of nanobiotechnology 2024-03, Vol.22 (1), p.122-122, Article 122
• Main Authors: Zhao, Yuying, Tan, Hanxu, Zhang, Juping, Zhan, Dandan, Yang, Bowen, Hong, Shicui, Pan, Bo, Wang, Neng, Chen, Tongkai, Shi, Yafei, Wang, Zhiyu
• Format: Article
• Language: English
• Subjects: 17β-Estradiol; Animals; Bioflavonoids; Breast cancer; Breast Neoplasms - pathology; Cancer therapies; Cell culture; Chemical properties; Drug delivery systems; Drug therapy; Drugs; Endocrine therapy; Estradiol - pharmacology; Estrogen sulfotransferase; Estrogens; Estrogens - metabolism; Estrogens - therapeutic use; Female; Flavanones; Flavones; Flavonoids; Galactose; Health aspects; Hormone therapy; Humans; Liver; Liver - metabolism; Liver targeting; Metabolites; Methods; Mice; Nanodrug; Nanoparticles; Naringenin; Oral administration; Permeability; Pharmaceutical research; Polyethylene glycol; Receptors, Estrogen - metabolism; Sex hormones; Side effects; Sulfotransferase; Tamoxifen - pharmacology; Therapy; Vehicles; Xenografts; Xenotransplantation; Zebrafish; Zebrafish - metabolism
• ISSN: 1477-3155; 1477-3155
• DOI: 10.1186/s12951-024-02356-0

Endocrine therapy is standard for hormone receptor-positive (HR ) breast cancer treatment. However, current strategies targeting estrogen signaling pay little attention to estradiol metabolism in the liver and is usually challenged by treatment failure. In a previous study, we demonstrated that the natural compound naringenin (NAR) inhibited HR breast cancer growth by activating estrogen sulfotransferase (EST) expression in the liver. Nevertheless, the poor water solubility, low bio-barrier permeability, and non-specific distribution limited its clinical application, particularly for oral administration. Here, a novel nano endocrine drug NAR-cell penetrating peptide-galactose nanoparticles (NCG) is reported. We demonstrated that NCG presented specific liver targeting and increased intestinal barrier permeability in both cell and zebrafish xenotransplantation models. Furthermore, NCG showed liver targeting and enterohepatic circulation in mouse breast cancer xenografts following oral administration. Notably, the cancer inhibition efficacy of NCG was superior to that of both NAR and the positive control tamoxifen, and was accompanied by increased hepatic EST expression and reduced estradiol levels in the liver, blood, and tumor tissue. Moreover, few side effects were observed after NCG treatment. Our findings reveal NCG as a promising candidate for endocrine therapy and highlight hepatic EST targeting as a novel therapeutic strategy for HR breast cancer.